12 completed, 3 unknown, 3 withdrawn, 1 active not recruiting. 11 Phase 2, 6 Phase 1, 2 Not applicable, 2 Phase 4, 1 Early Phase 1.
Follow Copper: new trials by email Literature Review of Copper trials Research Report on Copper
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform Temozolomide, Disulfiram, Copper - Glioblastoma Multiforme | Phase 2 | Not yet recruiting | Olympion Medical Center | 32 | 2027-01-01 | 2025-05-25 |
| Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety Tralement, Fixed-dose trace element combination product of zinc, copper, and selenious acid - Manganese Safety in Adults | Phase 4 | Withdrawn | American Regent, Inc. | 2025-02-01 | 2025-02-12 | |
| Tralement vs. Fixed-dose Trace Element Combination Product in Patients >3 to 17 Years of Age Requiring Long-term PN Tralement, Fixed-dose trace element combination product of zinc, copper, and selenious acid - Manganese Safety in Pediatric Patients | Phase 4 | Withdrawn | American Regent, Inc. | 2024-08-01 | 2024-11-15 | |
| Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms 18F-FDG, 64Cu-Dotatate - GEP-NET, Neuroendocrine Tumors | Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 200 | 2023-01-17 | 2023-11-22 |
| An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer Copper Cu 64 Anti-CEA Monoclonal Antibody M5A, Imaging Technique - Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8 | Early Phase 1 | Active not recruiting | City of Hope Medical Center | 14 | 2022-08-31 | 2026-06-08 |
| Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001 Cu(II)ATSM - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Collaborative Medicinal Development Pty Limited | 55 | 2020-03-19 | 2022-02-17 |
| Micronutrient Status Involved in Immunity in Elderly Patients With COVID-19 Selenium, Zinc and Copper, Vitamin A, D, E plasma concentrations during patient hospitalization - Covid19 | Completed | Hospices Civils de Lyon | 229 | 2020-03-01 | 2021-05-07 | |
| Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. Disulfiram, Vinorelbin, Cisplatin - Metastatic Breast Cancer | Phase 2 | Withdrawn | National Cancer Institute, Slovakia | 2020-01-01 | 2023-10-06 | |
| Contraceptive Hormones, Immunity, and Microbiome Evaluation Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel IUD (Lng-IUD) - Hormonal Contraception | Completed | Emory University | 155 | 2018-12-07 | 2024-10-29 | |
| Effect of the Incoportation of Copper and Zinc Nanoparticles Into Dental Adhesives Metal nanoparticles ( O Zn and Cu), Dental Adhesive pure - Caries, Dental | Not applicable | Unknown | University of Chile | 35 | 2018-12-01 | 2018-08-17 |
| ALS Treatment Extension Study Cu(II)ATSM - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Unknown | Collaborative Medicinal Development Pty Limited | 28 | 2018-01-18 | 2022-02-17 |
| Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Disulfiram - Breast Neoplasm Female, Metastatic Breast Cancer | Phase 2 | Completed | The Institute of Molecular and Translational Medicine, Czech Republic | 9 | 2017-09-29 | 2026-06-26 |
| Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease Cu(II)ATSM - Parkinson Disease | Phase 1 | Completed | Collaborative Medicinal Development Pty Limited | 31 | 2017-08-14 | 2020-03-17 |
| A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer Copper, Disulfiram, Copper gluconate - Prostate Cancer | Phase 1 | Terminated | Daniel George, MD | 9 | 2017-07-11 | 2021-09-16 |
| Disulfiram in Recurrent Glioblastoma Disulfiram, Copper, Alkylating Agents - Glioma, Glioblastoma | Phase 2 / Phase 3 | Completed | Sahlgrenska University Hospital | 88 | 2017-01-01 | 2021-03-18 |
| Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND Cu(II)ATSM - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 1 | Completed | Collaborative Medicinal Development Pty Limited | 50 | 2016-11-16 | 2020-03-17 |
| Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Disulfiram, Copper Gluconate, Surgery - Glioblastoma Multiforme | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 35 | 2016-06-15 | 2025-04-10 |
| Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy Ubiquinone, Combined antioxidant therapy, Placebo - Non-proliferative Diabetic Retinopathy, Diabetes Mellitus Type 2 | Phase 2 | Completed | University of Guadalajara | 61 | 2011-02-01 | 2014-02-13 |
| Safety Study of High Doses of Zinc in ALS Patients Zinc and Copper - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Completed | Phoenix Neurological Associates, LTD | 10 | 2010-10-01 | 2012-03-12 |
| Zinc and Biobehavioral Development in Early Childhood zinc, iron + copper - Child Development | Not applicable | Completed | Johns Hopkins Bloomberg School of Public Health | 251 | 2004-07-01 | 2014-09-09 |
Showing 20 of 21. Sign in to see all of them.
Amyotrophic Lateral Sclerosis (4) · Glioblastoma (3) · Breast Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · COVID-19 (1) · Carcinoma, Neuroendocrine (1) · Dental Caries (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Retinopathy (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Glioma (1) · Mitochondrial Diseases (1) · Motor Neuron Disease (1) · Neuroendocrine Tumors (1) · Parkinson Disease (1)
Collaborative Medicinal Development Pty Limited (4) · American Regent, Inc. (2) · City of Hope Medical Center (1) · Copenhagen University Hospital, Rigshospitalet (1) · Daniel George, MD (1) · Emory University (1) · Hospices Civils de Lyon (1) · Johns Hopkins Bloomberg School of Public Health (1) · National Cancer Institute, Slovakia (1) · Olympion Medical Center (1) · Phoenix Neurological Associates, LTD (1) · Sahlgrenska University Hospital (1) · The Institute of Molecular and Translational Medicine, Czech Republic (1) · University Hospital, Saarland (1) · University of Chile (1)
United States (5) · Australia (4) · Chile (1) · Czechia (1) · Denmark (1) · France (1) · Greece (1) · Mexico (1) · Norway (1) · Peru (1) · Slovakia (1) · Sweden (1)
Dominic Rowe, MD (3) · Adolfo D. Rodriguez-Carrizalez, M.Sc. (1) · Alicia Smith, PhD (1) · Andreas Kjaer, MD (1) · Andrew Evans, MD (1) · Asgeir S Jakola, MD, PhD (1) · Daniel George, MD (1) · David S Saperstein, MD (1) · Frank G Pajonk, M.D., lecturer (1) · Jeffrey Y Wong (1) · Jiayi Huang, M.D. (1) · Khaled Khechen, MD (1) · Laura E Caulfield, PhD (1)
PMID 22595020, PMID 24344045, PMID 24850625, PMID 30647912, PMID 36994923, PMID 37000452, PMID 38768767
P30CA033572 (1), R01HD045430 (1), R01HD095741 (1)